A practical reference on hGH fragment: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-03 and is reviewed periodically as new material appears.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
== External links == BBC website about the West murder case at the Wayback Machine (archived 15 June 2006) BBC report of West's conviction CourtTV Crime Library- Fred and Rosemary West Transcript of police interview
=== Types of vitamin A === It is "largely impossible" for provitamin carotenoids, such as beta-carotene, to cause toxicity, as their conversion to retinol is highly regulated. No vitamin A toxicity has ever been reported from ingestion of excessive amounts. Overconsumption of beta-carotene can only cause carotenosis, a harmless and reversible cosmetic condition in which the skin turns orange. Preformed vitamin A absorption and storage in the liver occur very efficiently until a pathologic condition develops. When ingested, 70–90% of preformed vitamin A is absorbed.
amplicon Any DNA or RNA sequence or fragment that is the source and/or product of an amplification reaction. The term is most frequently used to describe the numerous copied fragments that are the products of the polymerase chain reaction or ligase chain reaction, though it may also refer to sequences that are amplified naturally within a genome, e.g. by gene duplication.
== Scientific approach == In xenobiology, the aim is to design and construct biological systems that differ from their natural counterparts on one or more fundamental levels. Ideally these new-to-nature organisms would be different in every possible biochemical aspect exhibiting a very different genetic code. The long-term goal is to construct a cell that would store its genetic information not in DNA but in an alternative informational polymer consisting of xeno nucleic acids (XNA), different base pairs, using non-canonical amino acids and an altered genetic code. So far cells have been constructed that incorporate only one or two of these features.
The failure to gain improved rights for uitlanders (notably the dynamite tax) became a pretext for war and justification for a military build-up in Cape Colony. The case for war was developed and espoused as far away as the Australian colonies. Cape Colony Governor Sir Alfred Milner; Rhodes; Chamberlain; and mining syndicate owners such as Beit, Barney Barnato, and Lionel Phillips, favoured annexation of the Boer republics. Confident that the Boers would be quickly defeated, they planned and organised a short war, citing the uitlanders' grievances as the motivation. In contrast, the influence of the war party within the British government was limited. Prime Minister Lord Salisbury despised jingoism. He was uncertain of the abilities of the British Army. Despite his moral and practical reservations, Salisbury led the UK to war to preserve the Empire's prestige and a feeling of obligation to British South Africans. Salisbury detested the Boer treatment of native Africans, referring to the London Convention of 1884, following Britain's defeat in the first war, as an agreement "really in the interest of slavery". Salisbury was not alone in this. Roger Casement, already on the way to becoming an Irish Nationalist, was nevertheless happy to gather intelligence for the British against the Boers because of their cruelty to Africans.
Sources: en.wikipedia.org
== Early life and career == Kahn was born in Louisville, Kentucky. He received his undergraduate and medical degree from the University of Louisville in 1964 and 1968. He became interested in pursuing diabetes research while serving in several positions at the National Institutes of Health (NIH) from 1970 to 1981. He moved to Boston in 1981 when he was appointed Associate Professor of Medicine at Harvard Medical School and Research Director of the Joslin Diabetes Center. By 1984, he was promoted to Professor of Medicine and named the Mary K. Iacocca Professor of Medicine at Harvard Medical School in 1986.
== Education and career == Brodbelt has an undergraduate degree from the University of Virginia and earned her Ph.D. from Purdue University where she worked on gas phase ion chemistry using mass spectrometry. Following her Ph.D. she was a postdoc at the University of California, Santa Barbara before joining the University of Texas at Austin in 1989. As of 2016, she is the Roland Pettit Centennial Chair in the Department of Chemistry. She was the president of the American Society for Mass Spectrometry from 2014 to 2016.
Episode Two was released for Windows, Xbox 360 and PlayStation 3 on October 10, 2007, as part of the compilation The Orange Box. It was distributed digitally on Steam and at retail by Electronic Arts. Episode Two focuses on expansive environments, travel and less linear play. As Freeman, the player travels with Alyx into the surrounding countryside, pursued by Combine forces. Episode Two's new technologies and gameplay features were praised by reviewers; however, though it was significantly longer than Episode 1, the length was again a point of criticism.
In boosted fission weapons a mix of 2H and 3H is heated until there is thermonuclear fusion to produce helium and free neutrons. These fast neutrons then cause further fission, creating "boosting". In 1951, in Operation Greenhouse, a prototype named George, validated the proof of concept for such a weapon. However, the first true boosted fission bomb, Greenhouse Item, was successfully tested in 1952, giving a 45.5-kiloton yield, nearly double that of an unboosted bomb. The United States stopped producing tritium in nuclear reactors in 1988, but nuclear tests in the 1950s added large spikes of radionuclides to the air, especially carbon-14 and 3H. This complicated measurements for geologists using carbon dating. However, some oceanographers benefited from the 3H increase, using the signal in the water to trace physical mixing of water masses.
In biochemistry, phosphorylation is described as the "transfer of a phosphate group" from a donor to an acceptor or the addition of a phosphate group to a molecule. A common phosphorylating agent (phosphate donor) is ATP and a common family of acceptor are alcohols:
Sources: en.wikipedia.org
In the nonoverlapping triangles APB, BPC, CPD, DPA formed by the diagonals in a convex quadrilateral ABCD, where the diagonals intersect at P, there are the following characterizations of tangential quadrilaterals. Let r1, r2, r3, and r4 denote the radii of the incircles in the four triangles APB, BPC, CPD, and DPA respectively. Chao and Simeonov proved that the quadrilateral is tangential if and only if
Leaf protein concentrate (LPC) is a proteinaceous edible mass extracted from leaves. It can be a lucrative source of low-cost and sustainable protein for food as well as feed applications. Although the proteinaceous extracts from leaves have been described as early as 1773 by Rouelle, large scale extraction and production of LPC was pioneered post the World War II. In fact, many innovations and advances made with regards to LPC production occurred in parallel to the Green Revolution. In some respects, these two technologies were complimentary in that the Green Revolution sought to increase agrarian productivity through increased crop yields via fertiliser use, mechanisation and genetically modified crops, while LPC offered the means to better utilise available agrarian resources through efficient protein extraction.
== Common ingredients == Antiscalants could be broadly classified into 3 main categories: phosphorus based AS, synthetic polymeric AS and natural green AS. Common active ingredients include phosphonates, polyphosphates, polymers, aminophosphonates and organic acids. Antiscalants typically contain a combination of active ingredients that interfere with the crystallization process of scale-forming salts. Phosphorus-based antiscalants have the largest application use globally, and they can be further classified into phosphorus-based and phosphonate-based AS. Green antiscalants usually contain natural polymers such as starch and are recently being more widely investigated due to discharge requirements. Polymer-based AS are synthetic polymers that have functional groups like carboxylic acid groups, acrylic acid, sulfonic acid, and phosphonic acid groups. Common global suppliers of antiscalants include Kurita Water Industries, Avista, Nalco, and Veolia.
=== 16 May === Two people were killed in Russian attacks in Kharkiv Oblast. One person was killed in a separate attack in Kherson Oblast. Ukrainian media reported that the HUR launched a drone attack on a weapons manufacturing plant in Russia's Tula Oblast. President Zelenskyy arrived in Kharkiv to meet with the military leadership, saying that the situation in Kharkiv Oblast was "generally under control" but the area remained "extremely difficult". A police official in Kharkiv said that up to 40 civilians in Vovchansk who attempted to flee shelling were captured by Russian forces and were reportedly imprisoned in basements where they are interrogated by alleged FSB agents. According to Ukrainian Interior Minister Ihor Klymenko, Russian soldiers in Vovchansk executed a civilian prisoner after he refused to obey orders and attempted to flee. Police opened a criminal investigation on the grounds of violations of laws of war. Ukrainian soldiers in the Kharkiv front reported that they had "never seen anything close to the number of Lancets (drones) flying" compared to earlier battles. The ISW assessed that the "tempo of Russian offensive operations in the area continues to decrease".
== Factors influencing bioavailability == The absolute bioavailability of a drug, when administered by an extravascular route, is usually less than one (i.e., F< 100%). Various physiological factors reduce the availability of drugs prior to their entry into the systemic circulation. Whether a drug is taken with or without food will also affect absorption, other drugs taken concurrently may alter absorption and first-pass metabolism, intestinal motility alters the dissolution of the drug and may affect the degree of chemical degradation of the drug by intestinal microflora. Disease states affecting liver metabolism or gastrointestinal function will also have an effect. Other factors may include, but are not limited to:
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.